Global Biologics for Obstructive Airway Diseases Market 2026 by Company, Regions, Type and Application, Forecast to 2032
According to our (Global Info Research) latest study, the global Biologics for Obstructive Airway Diseases market size was valued at US$ 12533 million in 2025 and is forecast to a readjusted size of US$ 22862 million by 2032 with a CAGR of 8.1% during review period.
Biologics for Obstructive Airway Diseases refer to biologic medicines produced using biotechnology that exert therapeutic effects by specifically modulating targets or signaling pathways associated with airway inflammation, allergic responses, and immune reactions, and that are classified under R03, Drugs for Obstructive Airway Diseases, of the World Health Organization Anatomical Therapeutic Chemical Classification System. These medicines primarily act by targeting key inflammatory mediators or receptors, including immunoglobulin E, interleukin-5, the interleukin-5 receptor, and thymic stromal lymphopoietin, thereby reducing airway inflammation, eosinophil activation, and allergic responses. They are mainly used to reduce disease exacerbations, improve lung function, and enhance disease control in severe asthma, chronic obstructive pulmonary disease, and other obstructive airway diseases covered by relevant approved indications.
For the purposes of this report, a product is included only when it meets both criteria: it is classified under ATC R03 and it qualifies as a biologic medicine. Inhaled corticosteroids, bronchodilators, leukotriene receptor antagonists, and other small-molecule medicines within R03 are excluded. Biologic medicines outside R03 are also excluded even if they are used to treat asthma, chronic obstructive pulmonary disease, or other respiratory diseases. Both originator biologics and biosimilars are included under their corresponding active substances and ATC classifications.
Biologics for obstructive airway diseases are biologic medicines produced using biotechnology and classified under R03, Drugs for Obstructive Airway Diseases, of the World Health Organization Anatomical Therapeutic Chemical Classification System. These medicines act primarily by specifically targeting key molecules involved in airway inflammation, allergic responses, and immune regulation. Current major targets include immunoglobulin E, interleukin-5, the interleukin-5 receptor, and thymic stromal lymphopoietin. They are mainly used for severe asthma, selected forms of chronic obstructive pulmonary disease, and other obstructive airway diseases covered by relevant approved indications. The industry excludes inhaled corticosteroids, bronchodilators, and other small-molecule drugs within R03, as well as respiratory biologics whose ATC classifications fall outside R03.
By product structure, monoclonal antibodies account for the dominant share of biologics for obstructive airway diseases. Representative active substances include omalizumab, mepolizumab, reslizumab, benralizumab, tezepelumab, and depemokimab. These products achieve differentiated therapeutic effects by inhibiting immunoglobulin E, eosinophil-related pathways, or upstream inflammatory mediators. Immunoglobulin E-targeted therapies have been commercialized for a relatively long period and are entering a market environment in which originator products and biosimilars coexist. Interleukin-5 and interleukin-5 receptor therapies primarily target severe eosinophilic asthma, while thymic stromal lymphopoietin-targeted therapies act further upstream in the inflammatory cascade and may therefore cover a broader patient population.
By therapeutic application, severe asthma currently represents the principal area of use. Biologics are generally used in patients whose disease remains inadequately controlled with conventional inhaled therapies and who exhibit identifiable allergic, eosinophilic, or other inflammatory phenotypes. As biomarker testing and patient stratification improve, clinical management is shifting from conventional symptom control toward precision treatment based on disease phenotype and underlying inflammatory mechanisms. At the same time, selected biologics are expanding into chronic obstructive pulmonary disease, particularly among patients with eosinophilic inflammation, creating an additional source of industry growth.
Subcutaneous injection is currently the dominant route of administration. Several products are available in prefilled syringes or autoinjectors, allowing treatment to gradually shift from hospitals and specialty clinics toward homecare settings. A limited number of products continue to be administered by intravenous infusion, primarily in hospitals or specialized healthcare facilities. Longer dosing intervals, more convenient delivery devices, and improved self-administration capabilities are becoming important competitive attributes for next-generation therapies, helping improve long-term adherence and reduce the treatment burden on patients.
The upstream supply chain primarily includes cell lines, culture media, single-use bioprocess consumables, bioreactors, filtration systems, chromatography resins, buffer materials, syringes, and other sterile packaging components. Midstream activities include cell culture, harvest, purification, viral clearance, drug substance preparation, formulation, aseptic filling, quality testing, and batch release. Downstream access is primarily through hospitals, respiratory and allergy specialty clinics, specialty pharmacies, and homecare settings. Because these products require stringent control of protein structure, purity, biological activity, aggregation, impurities, and sterility, manufacturing is subject to demanding quality management and batch consistency requirements.
From a manufacturing perspective, most products are produced using mammalian cell expression systems. Commercial manufacturing generally involves cell culture in bioreactors followed by multi-stage filtration and chromatography purification. Individual bioreactors in commercial production lines commonly range from approximately 2,000 to 20,000 liters, while large manufacturing facilities typically operate multiple bioreactors together with associated downstream purification systems. There is no single standardized annual capacity per production line, as effective output depends on antibody titer, culture cycle, batch frequency, bioreactor configuration, purification yield, and facility utilization. Large stainless-steel systems provide significant economies of scale for mature high-volume antibody products, whereas single-use systems offer greater flexibility for multiproduct and smaller-batch manufacturing.
Major cost components include culture media and single-use consumables, chromatography resins, facility depreciation, labor, quality testing, utilities, fill-finish operations, packaging, and cold-chain logistics. Unit manufacturing costs can decline materially as production scale and antibody titers increase, giving mature commercial products substantial economies of scale. Innovative originator biologics typically benefit from premium pricing and strong patent protection, and gross margins for mature products can generally reach approximately 60% to 85%. Biosimilars typically generate lower gross margins because of stronger price competition and distribution costs, although manufacturers with efficient large-scale production can still maintain attractive profitability.
The industry is characterized by high research and development, manufacturing, and regulatory barriers. Companies must not only complete complex clinical development and indication-specific validation but also establish biologics manufacturing systems that comply with good manufacturing practice requirements and consistently maintain product quality, aseptic control, and pharmacovigilance standards. For biosimilars, manufacturers must demonstrate a high degree of structural and functional similarity to the reference product and satisfy regulatory requirements concerning quality, clinical comparability, and immunogenicity. Companies with established cell culture, purification, and analytical quality platforms therefore possess significant competitive advantages.
The global competitive landscape remains relatively concentrated, with major originator products controlled by a limited number of large multinational pharmaceutical companies. These companies maintain their positions through extensive clinical evidence, indication expansion, brand recognition, and global commercialization networks. As patents for earlier products expire, mature molecules such as omalizumab are entering biosimilar competition, while biologics manufacturers from South Korea, China, and other regions are increasingly participating in the market. In China, the market remains in a stage of domestic substitution and increasing biologic penetration, with local companies initially targeting mature molecules such as omalizumab while expanding large-scale antibody manufacturing and commercialization capabilities.
Distribution and end-use patterns are highly specialized. Patients are commonly selected using serum immunoglobulin E levels, peripheral blood eosinophil counts, allergen testing, and other clinical indicators, making product use highly dependent on respiratory specialists, allergists, and other specialized physicians. As prefilled formulations, self-injection products, and remote patient-management models become more widely adopted, the proportion of home-based treatment is expected to increase. However, initial administration, response assessment, and monitoring for serious adverse events are expected to remain concentrated in professional healthcare settings.
Future industry growth will be driven primarily by higher penetration of biologic therapies in severe asthma, expansion into chronic obstructive pulmonary disease, development of novel inflammatory targets, biomarker-driven precision patient stratification, and improved patient access in emerging markets. At the same time, biosimilar competition for mature products such as omalizumab will continue to exert downward pressure on pricing, gradually shifting market growth from price-driven expansion toward growth in treated patient populations and new indications. Competition is therefore expected to move beyond efficacy at a single target toward a broader combination of patient coverage, lower dosing frequency, more convenient administration, long-term safety, and overall cost effectiveness.
Global Biologics for Obstructive Airway Diseases market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Biologics for Obstructive Airway Diseases market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Biologics for Obstructive Airway Diseases market shares of main players, in revenue ($ Million), 2021-2026
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Biologics for Obstructive Airway Diseases market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Chapter 2, to profile the top players of Biologics for Obstructive Airway Diseases, with revenue, gross margin, and global market share of Biologics for Obstructive Airway Diseases from 2021 to 2026.
Chapter 3, the Biologics for Obstructive Airway Diseases competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Biologics for Obstructive Airway Diseases market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Biologics for Obstructive Airway Diseases.
Chapter 13, to describe Biologics for Obstructive Airway Diseases research findings and conclusion.
Biologics for Obstructive Airway Diseases refer to biologic medicines produced using biotechnology that exert therapeutic effects by specifically modulating targets or signaling pathways associated with airway inflammation, allergic responses, and immune reactions, and that are classified under R03, Drugs for Obstructive Airway Diseases, of the World Health Organization Anatomical Therapeutic Chemical Classification System. These medicines primarily act by targeting key inflammatory mediators or receptors, including immunoglobulin E, interleukin-5, the interleukin-5 receptor, and thymic stromal lymphopoietin, thereby reducing airway inflammation, eosinophil activation, and allergic responses. They are mainly used to reduce disease exacerbations, improve lung function, and enhance disease control in severe asthma, chronic obstructive pulmonary disease, and other obstructive airway diseases covered by relevant approved indications.
For the purposes of this report, a product is included only when it meets both criteria: it is classified under ATC R03 and it qualifies as a biologic medicine. Inhaled corticosteroids, bronchodilators, leukotriene receptor antagonists, and other small-molecule medicines within R03 are excluded. Biologic medicines outside R03 are also excluded even if they are used to treat asthma, chronic obstructive pulmonary disease, or other respiratory diseases. Both originator biologics and biosimilars are included under their corresponding active substances and ATC classifications.
Biologics for obstructive airway diseases are biologic medicines produced using biotechnology and classified under R03, Drugs for Obstructive Airway Diseases, of the World Health Organization Anatomical Therapeutic Chemical Classification System. These medicines act primarily by specifically targeting key molecules involved in airway inflammation, allergic responses, and immune regulation. Current major targets include immunoglobulin E, interleukin-5, the interleukin-5 receptor, and thymic stromal lymphopoietin. They are mainly used for severe asthma, selected forms of chronic obstructive pulmonary disease, and other obstructive airway diseases covered by relevant approved indications. The industry excludes inhaled corticosteroids, bronchodilators, and other small-molecule drugs within R03, as well as respiratory biologics whose ATC classifications fall outside R03.
By product structure, monoclonal antibodies account for the dominant share of biologics for obstructive airway diseases. Representative active substances include omalizumab, mepolizumab, reslizumab, benralizumab, tezepelumab, and depemokimab. These products achieve differentiated therapeutic effects by inhibiting immunoglobulin E, eosinophil-related pathways, or upstream inflammatory mediators. Immunoglobulin E-targeted therapies have been commercialized for a relatively long period and are entering a market environment in which originator products and biosimilars coexist. Interleukin-5 and interleukin-5 receptor therapies primarily target severe eosinophilic asthma, while thymic stromal lymphopoietin-targeted therapies act further upstream in the inflammatory cascade and may therefore cover a broader patient population.
By therapeutic application, severe asthma currently represents the principal area of use. Biologics are generally used in patients whose disease remains inadequately controlled with conventional inhaled therapies and who exhibit identifiable allergic, eosinophilic, or other inflammatory phenotypes. As biomarker testing and patient stratification improve, clinical management is shifting from conventional symptom control toward precision treatment based on disease phenotype and underlying inflammatory mechanisms. At the same time, selected biologics are expanding into chronic obstructive pulmonary disease, particularly among patients with eosinophilic inflammation, creating an additional source of industry growth.
Subcutaneous injection is currently the dominant route of administration. Several products are available in prefilled syringes or autoinjectors, allowing treatment to gradually shift from hospitals and specialty clinics toward homecare settings. A limited number of products continue to be administered by intravenous infusion, primarily in hospitals or specialized healthcare facilities. Longer dosing intervals, more convenient delivery devices, and improved self-administration capabilities are becoming important competitive attributes for next-generation therapies, helping improve long-term adherence and reduce the treatment burden on patients.
The upstream supply chain primarily includes cell lines, culture media, single-use bioprocess consumables, bioreactors, filtration systems, chromatography resins, buffer materials, syringes, and other sterile packaging components. Midstream activities include cell culture, harvest, purification, viral clearance, drug substance preparation, formulation, aseptic filling, quality testing, and batch release. Downstream access is primarily through hospitals, respiratory and allergy specialty clinics, specialty pharmacies, and homecare settings. Because these products require stringent control of protein structure, purity, biological activity, aggregation, impurities, and sterility, manufacturing is subject to demanding quality management and batch consistency requirements.
From a manufacturing perspective, most products are produced using mammalian cell expression systems. Commercial manufacturing generally involves cell culture in bioreactors followed by multi-stage filtration and chromatography purification. Individual bioreactors in commercial production lines commonly range from approximately 2,000 to 20,000 liters, while large manufacturing facilities typically operate multiple bioreactors together with associated downstream purification systems. There is no single standardized annual capacity per production line, as effective output depends on antibody titer, culture cycle, batch frequency, bioreactor configuration, purification yield, and facility utilization. Large stainless-steel systems provide significant economies of scale for mature high-volume antibody products, whereas single-use systems offer greater flexibility for multiproduct and smaller-batch manufacturing.
Major cost components include culture media and single-use consumables, chromatography resins, facility depreciation, labor, quality testing, utilities, fill-finish operations, packaging, and cold-chain logistics. Unit manufacturing costs can decline materially as production scale and antibody titers increase, giving mature commercial products substantial economies of scale. Innovative originator biologics typically benefit from premium pricing and strong patent protection, and gross margins for mature products can generally reach approximately 60% to 85%. Biosimilars typically generate lower gross margins because of stronger price competition and distribution costs, although manufacturers with efficient large-scale production can still maintain attractive profitability.
The industry is characterized by high research and development, manufacturing, and regulatory barriers. Companies must not only complete complex clinical development and indication-specific validation but also establish biologics manufacturing systems that comply with good manufacturing practice requirements and consistently maintain product quality, aseptic control, and pharmacovigilance standards. For biosimilars, manufacturers must demonstrate a high degree of structural and functional similarity to the reference product and satisfy regulatory requirements concerning quality, clinical comparability, and immunogenicity. Companies with established cell culture, purification, and analytical quality platforms therefore possess significant competitive advantages.
The global competitive landscape remains relatively concentrated, with major originator products controlled by a limited number of large multinational pharmaceutical companies. These companies maintain their positions through extensive clinical evidence, indication expansion, brand recognition, and global commercialization networks. As patents for earlier products expire, mature molecules such as omalizumab are entering biosimilar competition, while biologics manufacturers from South Korea, China, and other regions are increasingly participating in the market. In China, the market remains in a stage of domestic substitution and increasing biologic penetration, with local companies initially targeting mature molecules such as omalizumab while expanding large-scale antibody manufacturing and commercialization capabilities.
Distribution and end-use patterns are highly specialized. Patients are commonly selected using serum immunoglobulin E levels, peripheral blood eosinophil counts, allergen testing, and other clinical indicators, making product use highly dependent on respiratory specialists, allergists, and other specialized physicians. As prefilled formulations, self-injection products, and remote patient-management models become more widely adopted, the proportion of home-based treatment is expected to increase. However, initial administration, response assessment, and monitoring for serious adverse events are expected to remain concentrated in professional healthcare settings.
Future industry growth will be driven primarily by higher penetration of biologic therapies in severe asthma, expansion into chronic obstructive pulmonary disease, development of novel inflammatory targets, biomarker-driven precision patient stratification, and improved patient access in emerging markets. At the same time, biosimilar competition for mature products such as omalizumab will continue to exert downward pressure on pricing, gradually shifting market growth from price-driven expansion toward growth in treated patient populations and new indications. Competition is therefore expected to move beyond efficacy at a single target toward a broader combination of patient coverage, lower dosing frequency, more convenient administration, long-term safety, and overall cost effectiveness.
Report Scope
This report is a detailed and comprehensive analysis for global Biologics for Obstructive Airway Diseases market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.Key Features:
Global Biologics for Obstructive Airway Diseases market size and forecasts, in consumption value ($ Million), 2021-2032Global Biologics for Obstructive Airway Diseases market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Biologics for Obstructive Airway Diseases market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Biologics for Obstructive Airway Diseases market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Biologics for Obstructive Airway Diseases
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Biologics for Obstructive Airway Diseases market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segmentation
Market segment by Type
- gE Targeting
- IL-5 Targeting
- IL-5 Receptor Targeting
- TSLP Targeting
- Other Targets
Market segment by Therapeutic Application
- Asthma
- Chronic Obstructive Pulmonary Disease
- Other Obstructive Airway Diseases
Market segment by Product Status
- Originator Biologics
- Biosimilars
Market segment by Application
- Hospitals
- Specialty Clinics
- Homecare Settings
- Other Healthcare Settings
Market segment by players, this report covers
- Novartis AG
- Genentech, Inc. (Roche Group)
- GSK plc
- AstraZeneca plc
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- Celltrion, Inc.
- Taizhou Mabtech Pharmaceutical Co., Ltd.
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Grand Shuyang Life Sciences (Chengdu) Co., Ltd.
Market segment by regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
- South America (Brazil, Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Biologics for Obstructive Airway Diseases product scope, market overview, market estimation caveats and base year.Chapter 2, to profile the top players of Biologics for Obstructive Airway Diseases, with revenue, gross margin, and global market share of Biologics for Obstructive Airway Diseases from 2021 to 2026.
Chapter 3, the Biologics for Obstructive Airway Diseases competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Biologics for Obstructive Airway Diseases market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Biologics for Obstructive Airway Diseases.
Chapter 13, to describe Biologics for Obstructive Airway Diseases research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Biologics for Obstructive Airway Diseases by Type
1.3.1 Overview: Global Biologics for Obstructive Airway Diseases Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Biologics for Obstructive Airway Diseases Consumption Value Market Share by Type in 2025
1.3.3 gE Targeting
1.3.4 IL-5 Targeting
1.3.5 IL-5 Receptor Targeting
1.3.6 TSLP Targeting
1.3.7 Other Targets
1.4 Classification of Biologics for Obstructive Airway Diseases by Therapeutic Application
1.4.1 Overview: Global Biologics for Obstructive Airway Diseases Market Size by Therapeutic Application: 2021 Versus 2025 Versus 2032
1.4.2 Global Biologics for Obstructive Airway Diseases Consumption Value Market Share by Therapeutic Application in 2025
1.4.3 Asthma
1.4.4 Chronic Obstructive Pulmonary Disease
1.4.5 Other Obstructive Airway Diseases
1.5 Classification of Biologics for Obstructive Airway Diseases by Product Status
1.5.1 Overview: Global Biologics for Obstructive Airway Diseases Market Size by Product Status: 2021 Versus 2025 Versus 2032
1.5.2 Global Biologics for Obstructive Airway Diseases Consumption Value Market Share by Product Status in 2025
1.5.3 Originator Biologics
1.5.4 Biosimilars
1.6 Global Biologics for Obstructive Airway Diseases Market by Application
1.6.1 Overview: Global Biologics for Obstructive Airway Diseases Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Hospitals
1.6.3 Specialty Clinics
1.6.4 Homecare Settings
1.6.5 Other Healthcare Settings
1.7 Global Biologics for Obstructive Airway Diseases Market Size & Forecast
1.8 Global Biologics for Obstructive Airway Diseases Market Size and Forecast by Region
1.8.1 Global Biologics for Obstructive Airway Diseases Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global Biologics for Obstructive Airway Diseases Market Size by Region, (2021-2032)
1.8.3 North America Biologics for Obstructive Airway Diseases Market Size and Prospect (2021-2032)
1.8.4 Europe Biologics for Obstructive Airway Diseases Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific Biologics for Obstructive Airway Diseases Market Size and Prospect (2021-2032)
1.8.6 South America Biologics for Obstructive Airway Diseases Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa Biologics for Obstructive Airway Diseases Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Novartis AG
2.1.1 Novartis AG Details
2.1.2 Novartis AG Major Business
2.1.3 Novartis AG Biologics for Obstructive Airway Diseases Product and Solutions
2.1.4 Novartis AG Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Novartis AG Recent Developments and Future Plans
2.2 Genentech, Inc. (Roche Group)
2.2.1 Genentech, Inc. (Roche Group) Details
2.2.2 Genentech, Inc. (Roche Group) Major Business
2.2.3 Genentech, Inc. (Roche Group) Biologics for Obstructive Airway Diseases Product and Solutions
2.2.4 Genentech, Inc. (Roche Group) Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Genentech, Inc. (Roche Group) Recent Developments and Future Plans
2.3 GSK plc
2.3.1 GSK plc Details
2.3.2 GSK plc Major Business
2.3.3 GSK plc Biologics for Obstructive Airway Diseases Product and Solutions
2.3.4 GSK plc Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 GSK plc Recent Developments and Future Plans
2.4 AstraZeneca plc
2.4.1 AstraZeneca plc Details
2.4.2 AstraZeneca plc Major Business
2.4.3 AstraZeneca plc Biologics for Obstructive Airway Diseases Product and Solutions
2.4.4 AstraZeneca plc Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 AstraZeneca plc Recent Developments and Future Plans
2.5 Amgen Inc.
2.5.1 Amgen Inc. Details
2.5.2 Amgen Inc. Major Business
2.5.3 Amgen Inc. Biologics for Obstructive Airway Diseases Product and Solutions
2.5.4 Amgen Inc. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Amgen Inc. Recent Developments and Future Plans
2.6 Teva Pharmaceutical Industries Ltd.
2.6.1 Teva Pharmaceutical Industries Ltd. Details
2.6.2 Teva Pharmaceutical Industries Ltd. Major Business
2.6.3 Teva Pharmaceutical Industries Ltd. Biologics for Obstructive Airway Diseases Product and Solutions
2.6.4 Teva Pharmaceutical Industries Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans
2.7 Celltrion, Inc.
2.7.1 Celltrion, Inc. Details
2.7.2 Celltrion, Inc. Major Business
2.7.3 Celltrion, Inc. Biologics for Obstructive Airway Diseases Product and Solutions
2.7.4 Celltrion, Inc. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Celltrion, Inc. Recent Developments and Future Plans
2.8 Taizhou Mabtech Pharmaceutical Co., Ltd.
2.8.1 Taizhou Mabtech Pharmaceutical Co., Ltd. Details
2.8.2 Taizhou Mabtech Pharmaceutical Co., Ltd. Major Business
2.8.3 Taizhou Mabtech Pharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Product and Solutions
2.8.4 Taizhou Mabtech Pharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Taizhou Mabtech Pharmaceutical Co., Ltd. Recent Developments and Future Plans
2.9 CSPC Megalith Biopharmaceutical Co., Ltd.
2.9.1 CSPC Megalith Biopharmaceutical Co., Ltd. Details
2.9.2 CSPC Megalith Biopharmaceutical Co., Ltd. Major Business
2.9.3 CSPC Megalith Biopharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Product and Solutions
2.9.4 CSPC Megalith Biopharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 CSPC Megalith Biopharmaceutical Co., Ltd. Recent Developments and Future Plans
2.10 Grand Shuyang Life Sciences (Chengdu) Co., Ltd.
2.10.1 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Details
2.10.2 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Major Business
2.10.3 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Biologics for Obstructive Airway Diseases Product and Solutions
2.10.4 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Biologics for Obstructive Airway Diseases Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Biologics for Obstructive Airway Diseases by Company Revenue
3.2.2 Top 3 Biologics for Obstructive Airway Diseases Players Market Share in 2025
3.2.3 Top 6 Biologics for Obstructive Airway Diseases Players Market Share in 2025
3.3 Biologics for Obstructive Airway Diseases Market: Overall Company Footprint Analysis
3.3.1 Biologics for Obstructive Airway Diseases Market: Region Footprint
3.3.2 Biologics for Obstructive Airway Diseases Market: Company Product Type Footprint
3.3.3 Biologics for Obstructive Airway Diseases Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Biologics for Obstructive Airway Diseases Consumption Value and Market Share by Type (2021-2026)
4.2 Global Biologics for Obstructive Airway Diseases Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Biologics for Obstructive Airway Diseases Consumption Value Market Share by Application (2021-2026)
5.2 Global Biologics for Obstructive Airway Diseases Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Biologics for Obstructive Airway Diseases Consumption Value by Type (2021-2032)
6.2 North America Biologics for Obstructive Airway Diseases Market Size by Application (2021-2032)
6.3 North America Biologics for Obstructive Airway Diseases Market Size by Country
6.3.1 North America Biologics for Obstructive Airway Diseases Consumption Value by Country (2021-2032)
6.3.2 United States Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
6.3.3 Canada Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
6.3.4 Mexico Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Biologics for Obstructive Airway Diseases Consumption Value by Type (2021-2032)
7.2 Europe Biologics for Obstructive Airway Diseases Consumption Value by Application (2021-2032)
7.3 Europe Biologics for Obstructive Airway Diseases Market Size by Country
7.3.1 Europe Biologics for Obstructive Airway Diseases Consumption Value by Country (2021-2032)
7.3.2 Germany Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
7.3.3 France Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
7.3.5 Russia Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
7.3.6 Italy Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Biologics for Obstructive Airway Diseases Market Size by Region
8.3.1 Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value by Region (2021-2032)
8.3.2 China Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
8.3.3 Japan Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
8.3.4 South Korea Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
8.3.5 India Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
8.3.7 Australia Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Biologics for Obstructive Airway Diseases Consumption Value by Type (2021-2032)
9.2 South America Biologics for Obstructive Airway Diseases Consumption Value by Application (2021-2032)
9.3 South America Biologics for Obstructive Airway Diseases Market Size by Country
9.3.1 South America Biologics for Obstructive Airway Diseases Consumption Value by Country (2021-2032)
9.3.2 Brazil Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
9.3.3 Argentina Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Biologics for Obstructive Airway Diseases Market Size by Country
10.3.1 Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value by Country (2021-2032)
10.3.2 Turkey Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
10.3.4 UAE Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Biologics for Obstructive Airway Diseases Market Drivers
11.2 Biologics for Obstructive Airway Diseases Market Restraints
11.3 Biologics for Obstructive Airway Diseases Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Biologics for Obstructive Airway Diseases Industry Chain
12.2 Biologics for Obstructive Airway Diseases Upstream Analysis
12.3 Biologics for Obstructive Airway Diseases Midstream Analysis
12.4 Biologics for Obstructive Airway Diseases Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Biologics for Obstructive Airway Diseases by Type
1.3.1 Overview: Global Biologics for Obstructive Airway Diseases Market Size by Type: 2021 Versus 2025 Versus 2032
1.3.2 Global Biologics for Obstructive Airway Diseases Consumption Value Market Share by Type in 2025
1.3.3 gE Targeting
1.3.4 IL-5 Targeting
1.3.5 IL-5 Receptor Targeting
1.3.6 TSLP Targeting
1.3.7 Other Targets
1.4 Classification of Biologics for Obstructive Airway Diseases by Therapeutic Application
1.4.1 Overview: Global Biologics for Obstructive Airway Diseases Market Size by Therapeutic Application: 2021 Versus 2025 Versus 2032
1.4.2 Global Biologics for Obstructive Airway Diseases Consumption Value Market Share by Therapeutic Application in 2025
1.4.3 Asthma
1.4.4 Chronic Obstructive Pulmonary Disease
1.4.5 Other Obstructive Airway Diseases
1.5 Classification of Biologics for Obstructive Airway Diseases by Product Status
1.5.1 Overview: Global Biologics for Obstructive Airway Diseases Market Size by Product Status: 2021 Versus 2025 Versus 2032
1.5.2 Global Biologics for Obstructive Airway Diseases Consumption Value Market Share by Product Status in 2025
1.5.3 Originator Biologics
1.5.4 Biosimilars
1.6 Global Biologics for Obstructive Airway Diseases Market by Application
1.6.1 Overview: Global Biologics for Obstructive Airway Diseases Market Size by Application: 2021 Versus 2025 Versus 2032
1.6.2 Hospitals
1.6.3 Specialty Clinics
1.6.4 Homecare Settings
1.6.5 Other Healthcare Settings
1.7 Global Biologics for Obstructive Airway Diseases Market Size & Forecast
1.8 Global Biologics for Obstructive Airway Diseases Market Size and Forecast by Region
1.8.1 Global Biologics for Obstructive Airway Diseases Market Size by Region: 2021 VS 2025 VS 2032
1.8.2 Global Biologics for Obstructive Airway Diseases Market Size by Region, (2021-2032)
1.8.3 North America Biologics for Obstructive Airway Diseases Market Size and Prospect (2021-2032)
1.8.4 Europe Biologics for Obstructive Airway Diseases Market Size and Prospect (2021-2032)
1.8.5 Asia-Pacific Biologics for Obstructive Airway Diseases Market Size and Prospect (2021-2032)
1.8.6 South America Biologics for Obstructive Airway Diseases Market Size and Prospect (2021-2032)
1.8.7 Middle East & Africa Biologics for Obstructive Airway Diseases Market Size and Prospect (2021-2032)
2 COMPANY PROFILES
2.1 Novartis AG
2.1.1 Novartis AG Details
2.1.2 Novartis AG Major Business
2.1.3 Novartis AG Biologics for Obstructive Airway Diseases Product and Solutions
2.1.4 Novartis AG Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.1.5 Novartis AG Recent Developments and Future Plans
2.2 Genentech, Inc. (Roche Group)
2.2.1 Genentech, Inc. (Roche Group) Details
2.2.2 Genentech, Inc. (Roche Group) Major Business
2.2.3 Genentech, Inc. (Roche Group) Biologics for Obstructive Airway Diseases Product and Solutions
2.2.4 Genentech, Inc. (Roche Group) Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.2.5 Genentech, Inc. (Roche Group) Recent Developments and Future Plans
2.3 GSK plc
2.3.1 GSK plc Details
2.3.2 GSK plc Major Business
2.3.3 GSK plc Biologics for Obstructive Airway Diseases Product and Solutions
2.3.4 GSK plc Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.3.5 GSK plc Recent Developments and Future Plans
2.4 AstraZeneca plc
2.4.1 AstraZeneca plc Details
2.4.2 AstraZeneca plc Major Business
2.4.3 AstraZeneca plc Biologics for Obstructive Airway Diseases Product and Solutions
2.4.4 AstraZeneca plc Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.4.5 AstraZeneca plc Recent Developments and Future Plans
2.5 Amgen Inc.
2.5.1 Amgen Inc. Details
2.5.2 Amgen Inc. Major Business
2.5.3 Amgen Inc. Biologics for Obstructive Airway Diseases Product and Solutions
2.5.4 Amgen Inc. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.5.5 Amgen Inc. Recent Developments and Future Plans
2.6 Teva Pharmaceutical Industries Ltd.
2.6.1 Teva Pharmaceutical Industries Ltd. Details
2.6.2 Teva Pharmaceutical Industries Ltd. Major Business
2.6.3 Teva Pharmaceutical Industries Ltd. Biologics for Obstructive Airway Diseases Product and Solutions
2.6.4 Teva Pharmaceutical Industries Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.6.5 Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans
2.7 Celltrion, Inc.
2.7.1 Celltrion, Inc. Details
2.7.2 Celltrion, Inc. Major Business
2.7.3 Celltrion, Inc. Biologics for Obstructive Airway Diseases Product and Solutions
2.7.4 Celltrion, Inc. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.7.5 Celltrion, Inc. Recent Developments and Future Plans
2.8 Taizhou Mabtech Pharmaceutical Co., Ltd.
2.8.1 Taizhou Mabtech Pharmaceutical Co., Ltd. Details
2.8.2 Taizhou Mabtech Pharmaceutical Co., Ltd. Major Business
2.8.3 Taizhou Mabtech Pharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Product and Solutions
2.8.4 Taizhou Mabtech Pharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.8.5 Taizhou Mabtech Pharmaceutical Co., Ltd. Recent Developments and Future Plans
2.9 CSPC Megalith Biopharmaceutical Co., Ltd.
2.9.1 CSPC Megalith Biopharmaceutical Co., Ltd. Details
2.9.2 CSPC Megalith Biopharmaceutical Co., Ltd. Major Business
2.9.3 CSPC Megalith Biopharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Product and Solutions
2.9.4 CSPC Megalith Biopharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.9.5 CSPC Megalith Biopharmaceutical Co., Ltd. Recent Developments and Future Plans
2.10 Grand Shuyang Life Sciences (Chengdu) Co., Ltd.
2.10.1 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Details
2.10.2 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Major Business
2.10.3 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Biologics for Obstructive Airway Diseases Product and Solutions
2.10.4 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Biologics for Obstructive Airway Diseases Revenue, Gross Margin and Market Share (2021-2026)
2.10.5 Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Biologics for Obstructive Airway Diseases Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
3.2.1 Market Share of Biologics for Obstructive Airway Diseases by Company Revenue
3.2.2 Top 3 Biologics for Obstructive Airway Diseases Players Market Share in 2025
3.2.3 Top 6 Biologics for Obstructive Airway Diseases Players Market Share in 2025
3.3 Biologics for Obstructive Airway Diseases Market: Overall Company Footprint Analysis
3.3.1 Biologics for Obstructive Airway Diseases Market: Region Footprint
3.3.2 Biologics for Obstructive Airway Diseases Market: Company Product Type Footprint
3.3.3 Biologics for Obstructive Airway Diseases Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Biologics for Obstructive Airway Diseases Consumption Value and Market Share by Type (2021-2026)
4.2 Global Biologics for Obstructive Airway Diseases Market Forecast by Type (2027-2032)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Biologics for Obstructive Airway Diseases Consumption Value Market Share by Application (2021-2026)
5.2 Global Biologics for Obstructive Airway Diseases Market Forecast by Application (2027-2032)
6 NORTH AMERICA
6.1 North America Biologics for Obstructive Airway Diseases Consumption Value by Type (2021-2032)
6.2 North America Biologics for Obstructive Airway Diseases Market Size by Application (2021-2032)
6.3 North America Biologics for Obstructive Airway Diseases Market Size by Country
6.3.1 North America Biologics for Obstructive Airway Diseases Consumption Value by Country (2021-2032)
6.3.2 United States Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
6.3.3 Canada Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
6.3.4 Mexico Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
7 EUROPE
7.1 Europe Biologics for Obstructive Airway Diseases Consumption Value by Type (2021-2032)
7.2 Europe Biologics for Obstructive Airway Diseases Consumption Value by Application (2021-2032)
7.3 Europe Biologics for Obstructive Airway Diseases Market Size by Country
7.3.1 Europe Biologics for Obstructive Airway Diseases Consumption Value by Country (2021-2032)
7.3.2 Germany Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
7.3.3 France Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
7.3.4 United Kingdom Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
7.3.5 Russia Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
7.3.6 Italy Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
8 ASIA-PACIFIC
8.1 Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Biologics for Obstructive Airway Diseases Market Size by Region
8.3.1 Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value by Region (2021-2032)
8.3.2 China Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
8.3.3 Japan Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
8.3.4 South Korea Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
8.3.5 India Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
8.3.6 Southeast Asia Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
8.3.7 Australia Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
9 SOUTH AMERICA
9.1 South America Biologics for Obstructive Airway Diseases Consumption Value by Type (2021-2032)
9.2 South America Biologics for Obstructive Airway Diseases Consumption Value by Application (2021-2032)
9.3 South America Biologics for Obstructive Airway Diseases Market Size by Country
9.3.1 South America Biologics for Obstructive Airway Diseases Consumption Value by Country (2021-2032)
9.3.2 Brazil Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
9.3.3 Argentina Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Biologics for Obstructive Airway Diseases Market Size by Country
10.3.1 Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value by Country (2021-2032)
10.3.2 Turkey Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
10.3.3 Saudi Arabia Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
10.3.4 UAE Biologics for Obstructive Airway Diseases Market Size and Forecast (2021-2032)
11 MARKET DYNAMICS
11.1 Biologics for Obstructive Airway Diseases Market Drivers
11.2 Biologics for Obstructive Airway Diseases Market Restraints
11.3 Biologics for Obstructive Airway Diseases Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Biologics for Obstructive Airway Diseases Industry Chain
12.2 Biologics for Obstructive Airway Diseases Upstream Analysis
12.3 Biologics for Obstructive Airway Diseases Midstream Analysis
12.4 Biologics for Obstructive Airway Diseases Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Biologics for Obstructive Airway Diseases Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Biologics for Obstructive Airway Diseases Consumption Value by Therapeutic Application, (USD Million), 2021 & 2025 & 2032
Table 3. Global Biologics for Obstructive Airway Diseases Consumption Value by Product Status, (USD Million), 2021 & 2025 & 2032
Table 4. Global Biologics for Obstructive Airway Diseases Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Biologics for Obstructive Airway Diseases Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Biologics for Obstructive Airway Diseases Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Novartis AG Company Information, Head Office, and Major Competitors
Table 8. Novartis AG Major Business
Table 9. Novartis AG Biologics for Obstructive Airway Diseases Product and Solutions
Table 10. Novartis AG Biologics for Obstructive Airway Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Novartis AG Recent Developments and Future Plans
Table 12. Genentech, Inc. (Roche Group) Company Information, Head Office, and Major Competitors
Table 13. Genentech, Inc. (Roche Group) Major Business
Table 14. Genentech, Inc. (Roche Group) Biologics for Obstructive Airway Diseases Product and Solutions
Table 15. Genentech, Inc. (Roche Group) Biologics for Obstructive Airway Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Genentech, Inc. (Roche Group) Recent Developments and Future Plans
Table 17. GSK plc Company Information, Head Office, and Major Competitors
Table 18. GSK plc Major Business
Table 19. GSK plc Biologics for Obstructive Airway Diseases Product and Solutions
Table 20. GSK plc Biologics for Obstructive Airway Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. AstraZeneca plc Company Information, Head Office, and Major Competitors
Table 22. AstraZeneca plc Major Business
Table 23. AstraZeneca plc Biologics for Obstructive Airway Diseases Product and Solutions
Table 24. AstraZeneca plc Biologics for Obstructive Airway Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. AstraZeneca plc Recent Developments and Future Plans
Table 26. Amgen Inc. Company Information, Head Office, and Major Competitors
Table 27. Amgen Inc. Major Business
Table 28. Amgen Inc. Biologics for Obstructive Airway Diseases Product and Solutions
Table 29. Amgen Inc. Biologics for Obstructive Airway Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Amgen Inc. Recent Developments and Future Plans
Table 31. Teva Pharmaceutical Industries Ltd. Company Information, Head Office, and Major Competitors
Table 32. Teva Pharmaceutical Industries Ltd. Major Business
Table 33. Teva Pharmaceutical Industries Ltd. Biologics for Obstructive Airway Diseases Product and Solutions
Table 34. Teva Pharmaceutical Industries Ltd. Biologics for Obstructive Airway Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans
Table 36. Celltrion, Inc. Company Information, Head Office, and Major Competitors
Table 37. Celltrion, Inc. Major Business
Table 38. Celltrion, Inc. Biologics for Obstructive Airway Diseases Product and Solutions
Table 39. Celltrion, Inc. Biologics for Obstructive Airway Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. Celltrion, Inc. Recent Developments and Future Plans
Table 41. Taizhou Mabtech Pharmaceutical Co., Ltd. Company Information, Head Office, and Major Competitors
Table 42. Taizhou Mabtech Pharmaceutical Co., Ltd. Major Business
Table 43. Taizhou Mabtech Pharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Product and Solutions
Table 44. Taizhou Mabtech Pharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. Taizhou Mabtech Pharmaceutical Co., Ltd. Recent Developments and Future Plans
Table 46. CSPC Megalith Biopharmaceutical Co., Ltd. Company Information, Head Office, and Major Competitors
Table 47. CSPC Megalith Biopharmaceutical Co., Ltd. Major Business
Table 48. CSPC Megalith Biopharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Product and Solutions
Table 49. CSPC Megalith Biopharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. CSPC Megalith Biopharmaceutical Co., Ltd. Recent Developments and Future Plans
Table 51. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Company Information, Head Office, and Major Competitors
Table 52. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Major Business
Table 53. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Biologics for Obstructive Airway Diseases Product and Solutions
Table 54. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Biologics for Obstructive Airway Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Recent Developments and Future Plans
Table 56. Global Biologics for Obstructive Airway Diseases Revenue (USD Million) by Players (2021-2026)
Table 57. Global Biologics for Obstructive Airway Diseases Revenue Share by Players (2021-2026)
Table 58. Breakdown of Biologics for Obstructive Airway Diseases by Company Type (Tier 1, Tier 2, and Tier 3)
Table 59. Market Position of Players in Biologics for Obstructive Airway Diseases, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 60. Head Office of Key Biologics for Obstructive Airway Diseases Players
Table 61. Biologics for Obstructive Airway Diseases Market: Company Product Type Footprint
Table 62. Biologics for Obstructive Airway Diseases Market: Company Product Application Footprint
Table 63. Biologics for Obstructive Airway Diseases New Market Entrants and Barriers to Market Entry
Table 64. Biologics for Obstructive Airway Diseases Mergers, Acquisition, Agreements, and Collaborations
Table 65. Global Biologics for Obstructive Airway Diseases Consumption Value (USD Million) by Type (2021-2026)
Table 66. Global Biologics for Obstructive Airway Diseases Consumption Value Share by Type (2021-2026)
Table 67. Global Biologics for Obstructive Airway Diseases Consumption Value Forecast by Type (2027-2032)
Table 68. Global Biologics for Obstructive Airway Diseases Consumption Value by Application (2021-2026)
Table 69. Global Biologics for Obstructive Airway Diseases Consumption Value Forecast by Application (2027-2032)
Table 70. North America Biologics for Obstructive Airway Diseases Consumption Value by Type (2021-2026) & (USD Million)
Table 71. North America Biologics for Obstructive Airway Diseases Consumption Value by Type (2027-2032) & (USD Million)
Table 72. North America Biologics for Obstructive Airway Diseases Consumption Value by Application (2021-2026) & (USD Million)
Table 73. North America Biologics for Obstructive Airway Diseases Consumption Value by Application (2027-2032) & (USD Million)
Table 74. North America Biologics for Obstructive Airway Diseases Consumption Value by Country (2021-2026) & (USD Million)
Table 75. North America Biologics for Obstructive Airway Diseases Consumption Value by Country (2027-2032) & (USD Million)
Table 76. Europe Biologics for Obstructive Airway Diseases Consumption Value by Type (2021-2026) & (USD Million)
Table 77. Europe Biologics for Obstructive Airway Diseases Consumption Value by Type (2027-2032) & (USD Million)
Table 78. Europe Biologics for Obstructive Airway Diseases Consumption Value by Application (2021-2026) & (USD Million)
Table 79. Europe Biologics for Obstructive Airway Diseases Consumption Value by Application (2027-2032) & (USD Million)
Table 80. Europe Biologics for Obstructive Airway Diseases Consumption Value by Country (2021-2026) & (USD Million)
Table 81. Europe Biologics for Obstructive Airway Diseases Consumption Value by Country (2027-2032) & (USD Million)
Table 82. Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value by Type (2021-2026) & (USD Million)
Table 83. Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value by Type (2027-2032) & (USD Million)
Table 84. Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value by Application (2021-2026) & (USD Million)
Table 85. Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value by Application (2027-2032) & (USD Million)
Table 86. Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value by Region (2021-2026) & (USD Million)
Table 87. Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value by Region (2027-2032) & (USD Million)
Table 88. South America Biologics for Obstructive Airway Diseases Consumption Value by Type (2021-2026) & (USD Million)
Table 89. South America Biologics for Obstructive Airway Diseases Consumption Value by Type (2027-2032) & (USD Million)
Table 90. South America Biologics for Obstructive Airway Diseases Consumption Value by Application (2021-2026) & (USD Million)
Table 91. South America Biologics for Obstructive Airway Diseases Consumption Value by Application (2027-2032) & (USD Million)
Table 92. South America Biologics for Obstructive Airway Diseases Consumption Value by Country (2021-2026) & (USD Million)
Table 93. South America Biologics for Obstructive Airway Diseases Consumption Value by Country (2027-2032) & (USD Million)
Table 94. Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value by Type (2021-2026) & (USD Million)
Table 95. Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value by Type (2027-2032) & (USD Million)
Table 96. Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value by Application (2021-2026) & (USD Million)
Table 97. Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value by Application (2027-2032) & (USD Million)
Table 98. Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value by Country (2021-2026) & (USD Million)
Table 99. Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value by Country (2027-2032) & (USD Million)
Table 100. Global Key Players of Biologics for Obstructive Airway Diseases Upstream (Raw Materials)
Table 101. Global Biologics for Obstructive Airway Diseases Typical Customers
Table 1. Global Biologics for Obstructive Airway Diseases Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Table 2. Global Biologics for Obstructive Airway Diseases Consumption Value by Therapeutic Application, (USD Million), 2021 & 2025 & 2032
Table 3. Global Biologics for Obstructive Airway Diseases Consumption Value by Product Status, (USD Million), 2021 & 2025 & 2032
Table 4. Global Biologics for Obstructive Airway Diseases Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Table 5. Global Biologics for Obstructive Airway Diseases Consumption Value by Region (2021-2026) & (USD Million)
Table 6. Global Biologics for Obstructive Airway Diseases Consumption Value by Region (2027-2032) & (USD Million)
Table 7. Novartis AG Company Information, Head Office, and Major Competitors
Table 8. Novartis AG Major Business
Table 9. Novartis AG Biologics for Obstructive Airway Diseases Product and Solutions
Table 10. Novartis AG Biologics for Obstructive Airway Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 11. Novartis AG Recent Developments and Future Plans
Table 12. Genentech, Inc. (Roche Group) Company Information, Head Office, and Major Competitors
Table 13. Genentech, Inc. (Roche Group) Major Business
Table 14. Genentech, Inc. (Roche Group) Biologics for Obstructive Airway Diseases Product and Solutions
Table 15. Genentech, Inc. (Roche Group) Biologics for Obstructive Airway Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 16. Genentech, Inc. (Roche Group) Recent Developments and Future Plans
Table 17. GSK plc Company Information, Head Office, and Major Competitors
Table 18. GSK plc Major Business
Table 19. GSK plc Biologics for Obstructive Airway Diseases Product and Solutions
Table 20. GSK plc Biologics for Obstructive Airway Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 21. AstraZeneca plc Company Information, Head Office, and Major Competitors
Table 22. AstraZeneca plc Major Business
Table 23. AstraZeneca plc Biologics for Obstructive Airway Diseases Product and Solutions
Table 24. AstraZeneca plc Biologics for Obstructive Airway Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 25. AstraZeneca plc Recent Developments and Future Plans
Table 26. Amgen Inc. Company Information, Head Office, and Major Competitors
Table 27. Amgen Inc. Major Business
Table 28. Amgen Inc. Biologics for Obstructive Airway Diseases Product and Solutions
Table 29. Amgen Inc. Biologics for Obstructive Airway Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 30. Amgen Inc. Recent Developments and Future Plans
Table 31. Teva Pharmaceutical Industries Ltd. Company Information, Head Office, and Major Competitors
Table 32. Teva Pharmaceutical Industries Ltd. Major Business
Table 33. Teva Pharmaceutical Industries Ltd. Biologics for Obstructive Airway Diseases Product and Solutions
Table 34. Teva Pharmaceutical Industries Ltd. Biologics for Obstructive Airway Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 35. Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans
Table 36. Celltrion, Inc. Company Information, Head Office, and Major Competitors
Table 37. Celltrion, Inc. Major Business
Table 38. Celltrion, Inc. Biologics for Obstructive Airway Diseases Product and Solutions
Table 39. Celltrion, Inc. Biologics for Obstructive Airway Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 40. Celltrion, Inc. Recent Developments and Future Plans
Table 41. Taizhou Mabtech Pharmaceutical Co., Ltd. Company Information, Head Office, and Major Competitors
Table 42. Taizhou Mabtech Pharmaceutical Co., Ltd. Major Business
Table 43. Taizhou Mabtech Pharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Product and Solutions
Table 44. Taizhou Mabtech Pharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 45. Taizhou Mabtech Pharmaceutical Co., Ltd. Recent Developments and Future Plans
Table 46. CSPC Megalith Biopharmaceutical Co., Ltd. Company Information, Head Office, and Major Competitors
Table 47. CSPC Megalith Biopharmaceutical Co., Ltd. Major Business
Table 48. CSPC Megalith Biopharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Product and Solutions
Table 49. CSPC Megalith Biopharmaceutical Co., Ltd. Biologics for Obstructive Airway Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 50. CSPC Megalith Biopharmaceutical Co., Ltd. Recent Developments and Future Plans
Table 51. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Company Information, Head Office, and Major Competitors
Table 52. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Major Business
Table 53. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Biologics for Obstructive Airway Diseases Product and Solutions
Table 54. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Biologics for Obstructive Airway Diseases Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 55. Grand Shuyang Life Sciences (Chengdu) Co., Ltd. Recent Developments and Future Plans
Table 56. Global Biologics for Obstructive Airway Diseases Revenue (USD Million) by Players (2021-2026)
Table 57. Global Biologics for Obstructive Airway Diseases Revenue Share by Players (2021-2026)
Table 58. Breakdown of Biologics for Obstructive Airway Diseases by Company Type (Tier 1, Tier 2, and Tier 3)
Table 59. Market Position of Players in Biologics for Obstructive Airway Diseases, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
Table 60. Head Office of Key Biologics for Obstructive Airway Diseases Players
Table 61. Biologics for Obstructive Airway Diseases Market: Company Product Type Footprint
Table 62. Biologics for Obstructive Airway Diseases Market: Company Product Application Footprint
Table 63. Biologics for Obstructive Airway Diseases New Market Entrants and Barriers to Market Entry
Table 64. Biologics for Obstructive Airway Diseases Mergers, Acquisition, Agreements, and Collaborations
Table 65. Global Biologics for Obstructive Airway Diseases Consumption Value (USD Million) by Type (2021-2026)
Table 66. Global Biologics for Obstructive Airway Diseases Consumption Value Share by Type (2021-2026)
Table 67. Global Biologics for Obstructive Airway Diseases Consumption Value Forecast by Type (2027-2032)
Table 68. Global Biologics for Obstructive Airway Diseases Consumption Value by Application (2021-2026)
Table 69. Global Biologics for Obstructive Airway Diseases Consumption Value Forecast by Application (2027-2032)
Table 70. North America Biologics for Obstructive Airway Diseases Consumption Value by Type (2021-2026) & (USD Million)
Table 71. North America Biologics for Obstructive Airway Diseases Consumption Value by Type (2027-2032) & (USD Million)
Table 72. North America Biologics for Obstructive Airway Diseases Consumption Value by Application (2021-2026) & (USD Million)
Table 73. North America Biologics for Obstructive Airway Diseases Consumption Value by Application (2027-2032) & (USD Million)
Table 74. North America Biologics for Obstructive Airway Diseases Consumption Value by Country (2021-2026) & (USD Million)
Table 75. North America Biologics for Obstructive Airway Diseases Consumption Value by Country (2027-2032) & (USD Million)
Table 76. Europe Biologics for Obstructive Airway Diseases Consumption Value by Type (2021-2026) & (USD Million)
Table 77. Europe Biologics for Obstructive Airway Diseases Consumption Value by Type (2027-2032) & (USD Million)
Table 78. Europe Biologics for Obstructive Airway Diseases Consumption Value by Application (2021-2026) & (USD Million)
Table 79. Europe Biologics for Obstructive Airway Diseases Consumption Value by Application (2027-2032) & (USD Million)
Table 80. Europe Biologics for Obstructive Airway Diseases Consumption Value by Country (2021-2026) & (USD Million)
Table 81. Europe Biologics for Obstructive Airway Diseases Consumption Value by Country (2027-2032) & (USD Million)
Table 82. Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value by Type (2021-2026) & (USD Million)
Table 83. Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value by Type (2027-2032) & (USD Million)
Table 84. Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value by Application (2021-2026) & (USD Million)
Table 85. Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value by Application (2027-2032) & (USD Million)
Table 86. Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value by Region (2021-2026) & (USD Million)
Table 87. Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value by Region (2027-2032) & (USD Million)
Table 88. South America Biologics for Obstructive Airway Diseases Consumption Value by Type (2021-2026) & (USD Million)
Table 89. South America Biologics for Obstructive Airway Diseases Consumption Value by Type (2027-2032) & (USD Million)
Table 90. South America Biologics for Obstructive Airway Diseases Consumption Value by Application (2021-2026) & (USD Million)
Table 91. South America Biologics for Obstructive Airway Diseases Consumption Value by Application (2027-2032) & (USD Million)
Table 92. South America Biologics for Obstructive Airway Diseases Consumption Value by Country (2021-2026) & (USD Million)
Table 93. South America Biologics for Obstructive Airway Diseases Consumption Value by Country (2027-2032) & (USD Million)
Table 94. Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value by Type (2021-2026) & (USD Million)
Table 95. Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value by Type (2027-2032) & (USD Million)
Table 96. Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value by Application (2021-2026) & (USD Million)
Table 97. Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value by Application (2027-2032) & (USD Million)
Table 98. Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value by Country (2021-2026) & (USD Million)
Table 99. Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value by Country (2027-2032) & (USD Million)
Table 100. Global Key Players of Biologics for Obstructive Airway Diseases Upstream (Raw Materials)
Table 101. Global Biologics for Obstructive Airway Diseases Typical Customers
LIST OF FIGURES
Figure 1. Biologics for Obstructive Airway Diseases Picture
Figure 2. Global Biologics for Obstructive Airway Diseases Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Biologics for Obstructive Airway Diseases Consumption Value Market Share by Type in 2025
Figure 4. gE Targeting
Figure 5. IL-5 Targeting
Figure 6. IL-5 Receptor Targeting
Figure 7. TSLP Targeting
Figure 8. Other Targets
Figure 9. Global Biologics for Obstructive Airway Diseases Consumption Value by Therapeutic Application, (USD Million), 2021 & 2025 & 2032
Figure 10. Global Biologics for Obstructive Airway Diseases Consumption Value Market Share by Therapeutic Application in 2025
Figure 11. Asthma
Figure 12. Chronic Obstructive Pulmonary Disease
Figure 13. Other Obstructive Airway Diseases
Figure 14. Global Biologics for Obstructive Airway Diseases Consumption Value by Product Status, (USD Million), 2021 & 2025 & 2032
Figure 15. Global Biologics for Obstructive Airway Diseases Consumption Value Market Share by Product Status in 2025
Figure 16. Originator Biologics
Figure 17. Biosimilars
Figure 18. Global Biologics for Obstructive Airway Diseases Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 19. Biologics for Obstructive Airway Diseases Consumption Value Market Share by Application in 2025
Figure 20. Hospitals Picture
Figure 21. Specialty Clinics Picture
Figure 22. Homecare Settings Picture
Figure 23. Other Healthcare Settings Picture
Figure 24. Global Biologics for Obstructive Airway Diseases Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 25. Global Biologics for Obstructive Airway Diseases Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 26. Global Market Biologics for Obstructive Airway Diseases Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 27. Global Biologics for Obstructive Airway Diseases Consumption Value Market Share by Region (2021-2032)
Figure 28. Global Biologics for Obstructive Airway Diseases Consumption Value Market Share by Region in 2025
Figure 29. North America Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 30. Europe Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 31. Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 32. South America Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 33. Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 34. Company Three Recent Developments and Future Plans
Figure 35. Global Biologics for Obstructive Airway Diseases Revenue Share by Players in 2025
Figure 36. Biologics for Obstructive Airway Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 37. Market Share of Biologics for Obstructive Airway Diseases by Player Revenue in 2025
Figure 38. Top 3 Biologics for Obstructive Airway Diseases Players Market Share in 2025
Figure 39. Top 6 Biologics for Obstructive Airway Diseases Players Market Share in 2025
Figure 40. Global Biologics for Obstructive Airway Diseases Consumption Value Share by Type (2021-2026)
Figure 41. Global Biologics for Obstructive Airway Diseases Market Share Forecast by Type (2027-2032)
Figure 42. Global Biologics for Obstructive Airway Diseases Consumption Value Share by Application (2021-2026)
Figure 43. Global Biologics for Obstructive Airway Diseases Market Share Forecast by Application (2027-2032)
Figure 44. North America Biologics for Obstructive Airway Diseases Consumption Value Market Share by Type (2021-2032)
Figure 45. North America Biologics for Obstructive Airway Diseases Consumption Value Market Share by Application (2021-2032)
Figure 46. North America Biologics for Obstructive Airway Diseases Consumption Value Market Share by Country (2021-2032)
Figure 47. United States Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 48. Canada Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 49. Mexico Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 50. Europe Biologics for Obstructive Airway Diseases Consumption Value Market Share by Type (2021-2032)
Figure 51. Europe Biologics for Obstructive Airway Diseases Consumption Value Market Share by Application (2021-2032)
Figure 52. Europe Biologics for Obstructive Airway Diseases Consumption Value Market Share by Country (2021-2032)
Figure 53. Germany Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 54. France Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 55. United Kingdom Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 56. Russia Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 57. Italy Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 58. Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value Market Share by Type (2021-2032)
Figure 59. Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value Market Share by Application (2021-2032)
Figure 60. Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value Market Share by Region (2021-2032)
Figure 61. China Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 62. Japan Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 63. South Korea Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 64. India Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 65. Southeast Asia Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 66. Australia Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 67. South America Biologics for Obstructive Airway Diseases Consumption Value Market Share by Type (2021-2032)
Figure 68. South America Biologics for Obstructive Airway Diseases Consumption Value Market Share by Application (2021-2032)
Figure 69. South America Biologics for Obstructive Airway Diseases Consumption Value Market Share by Country (2021-2032)
Figure 70. Brazil Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 71. Argentina Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 72. Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value Market Share by Type (2021-2032)
Figure 73. Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value Market Share by Application (2021-2032)
Figure 74. Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value Market Share by Country (2021-2032)
Figure 75. Turkey Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 76. Saudi Arabia Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 77. UAE Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 78. Biologics for Obstructive Airway Diseases Market Drivers
Figure 79. Biologics for Obstructive Airway Diseases Market Restraints
Figure 80. Biologics for Obstructive Airway Diseases Market Trends
Figure 81. Porters Five Forces Analysis
Figure 82. Biologics for Obstructive Airway Diseases Industrial Chain
Figure 83. Methodology
Figure 84. Research Process and Data Source
Figure 1. Biologics for Obstructive Airway Diseases Picture
Figure 2. Global Biologics for Obstructive Airway Diseases Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 3. Global Biologics for Obstructive Airway Diseases Consumption Value Market Share by Type in 2025
Figure 4. gE Targeting
Figure 5. IL-5 Targeting
Figure 6. IL-5 Receptor Targeting
Figure 7. TSLP Targeting
Figure 8. Other Targets
Figure 9. Global Biologics for Obstructive Airway Diseases Consumption Value by Therapeutic Application, (USD Million), 2021 & 2025 & 2032
Figure 10. Global Biologics for Obstructive Airway Diseases Consumption Value Market Share by Therapeutic Application in 2025
Figure 11. Asthma
Figure 12. Chronic Obstructive Pulmonary Disease
Figure 13. Other Obstructive Airway Diseases
Figure 14. Global Biologics for Obstructive Airway Diseases Consumption Value by Product Status, (USD Million), 2021 & 2025 & 2032
Figure 15. Global Biologics for Obstructive Airway Diseases Consumption Value Market Share by Product Status in 2025
Figure 16. Originator Biologics
Figure 17. Biosimilars
Figure 18. Global Biologics for Obstructive Airway Diseases Consumption Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 19. Biologics for Obstructive Airway Diseases Consumption Value Market Share by Application in 2025
Figure 20. Hospitals Picture
Figure 21. Specialty Clinics Picture
Figure 22. Homecare Settings Picture
Figure 23. Other Healthcare Settings Picture
Figure 24. Global Biologics for Obstructive Airway Diseases Consumption Value, (USD Million): 2021 & 2025 & 2032
Figure 25. Global Biologics for Obstructive Airway Diseases Consumption Value and Forecast (2021-2032) & (USD Million)
Figure 26. Global Market Biologics for Obstructive Airway Diseases Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)
Figure 27. Global Biologics for Obstructive Airway Diseases Consumption Value Market Share by Region (2021-2032)
Figure 28. Global Biologics for Obstructive Airway Diseases Consumption Value Market Share by Region in 2025
Figure 29. North America Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 30. Europe Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 31. Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 32. South America Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 33. Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 34. Company Three Recent Developments and Future Plans
Figure 35. Global Biologics for Obstructive Airway Diseases Revenue Share by Players in 2025
Figure 36. Biologics for Obstructive Airway Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025
Figure 37. Market Share of Biologics for Obstructive Airway Diseases by Player Revenue in 2025
Figure 38. Top 3 Biologics for Obstructive Airway Diseases Players Market Share in 2025
Figure 39. Top 6 Biologics for Obstructive Airway Diseases Players Market Share in 2025
Figure 40. Global Biologics for Obstructive Airway Diseases Consumption Value Share by Type (2021-2026)
Figure 41. Global Biologics for Obstructive Airway Diseases Market Share Forecast by Type (2027-2032)
Figure 42. Global Biologics for Obstructive Airway Diseases Consumption Value Share by Application (2021-2026)
Figure 43. Global Biologics for Obstructive Airway Diseases Market Share Forecast by Application (2027-2032)
Figure 44. North America Biologics for Obstructive Airway Diseases Consumption Value Market Share by Type (2021-2032)
Figure 45. North America Biologics for Obstructive Airway Diseases Consumption Value Market Share by Application (2021-2032)
Figure 46. North America Biologics for Obstructive Airway Diseases Consumption Value Market Share by Country (2021-2032)
Figure 47. United States Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 48. Canada Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 49. Mexico Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 50. Europe Biologics for Obstructive Airway Diseases Consumption Value Market Share by Type (2021-2032)
Figure 51. Europe Biologics for Obstructive Airway Diseases Consumption Value Market Share by Application (2021-2032)
Figure 52. Europe Biologics for Obstructive Airway Diseases Consumption Value Market Share by Country (2021-2032)
Figure 53. Germany Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 54. France Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 55. United Kingdom Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 56. Russia Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 57. Italy Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 58. Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value Market Share by Type (2021-2032)
Figure 59. Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value Market Share by Application (2021-2032)
Figure 60. Asia-Pacific Biologics for Obstructive Airway Diseases Consumption Value Market Share by Region (2021-2032)
Figure 61. China Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 62. Japan Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 63. South Korea Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 64. India Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 65. Southeast Asia Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 66. Australia Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 67. South America Biologics for Obstructive Airway Diseases Consumption Value Market Share by Type (2021-2032)
Figure 68. South America Biologics for Obstructive Airway Diseases Consumption Value Market Share by Application (2021-2032)
Figure 69. South America Biologics for Obstructive Airway Diseases Consumption Value Market Share by Country (2021-2032)
Figure 70. Brazil Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 71. Argentina Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 72. Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value Market Share by Type (2021-2032)
Figure 73. Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value Market Share by Application (2021-2032)
Figure 74. Middle East & Africa Biologics for Obstructive Airway Diseases Consumption Value Market Share by Country (2021-2032)
Figure 75. Turkey Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 76. Saudi Arabia Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 77. UAE Biologics for Obstructive Airway Diseases Consumption Value (2021-2032) & (USD Million)
Figure 78. Biologics for Obstructive Airway Diseases Market Drivers
Figure 79. Biologics for Obstructive Airway Diseases Market Restraints
Figure 80. Biologics for Obstructive Airway Diseases Market Trends
Figure 81. Porters Five Forces Analysis
Figure 82. Biologics for Obstructive Airway Diseases Industrial Chain
Figure 83. Methodology
Figure 84. Research Process and Data Source
